Effect of rizatriptan and other triptans on the nausea symptom of migraine: A post hoc analysis

被引:27
|
作者
Lipton, RB
Pascual, J
Goadsby, PJ
Massiou, H
McCarroll, KA
Vandormael, K
Jiang, KH
Lines, CR
机构
[1] Innovat Med Res Inc, Stamford, CT 06905 USA
[2] Albert Einstein Coll Med, Bronx, NY USA
[3] Univ Hosp Marques de Valdecilla, Santander, Spain
[4] Neurol Inst, London, England
[5] Hop Lariboisiere, F-75475 Paris, France
[6] Merck Res Labs, West Point, PA USA
来源
HEADACHE | 2001年 / 41卷 / 08期
关键词
rizatriptan; sumatriptan; naratriptan; zolmitriptan; 5-HT1B/1D receptor agonists; migraine; nausea; baseline; emergent;
D O I
10.1046/j.1526-4610.2001.01139.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack. Methods.-Data from five randomized, placebo-controlled, double-blind clinical trials in which oral rizatriptan 10 mg was directly compared with oral sumatriptan 100 mg (N = 772), 50 mg (N = 1168), 25 mg (N = 1180), naratriptan 2.5 mg (N = 406), or zolmitriptan 2.5 mg (N = 571) for the acute treatment of a migraine attack were retrospectively analyzed. Migraine was diagnosed according to International Headache Society criteria. Presence or absence of nausea was recorded at baseline and at 0.5, 1, 1.5, and 2 hours after dosing. The end points analyzed were relief of nausea in those who had it at baseline and emergence of nausea in those who were free of it at baseline. Treatments were compared using odds ratios estimated from logistic regression models at 2 hours, and averaged odds ratios for the first 2 hours posttreatment. Results.-Approximately 60% of patients in each treatment group had nausea at baseline. In those patients with nausea at baseline, significantly more patients treated with rizatriptan 10 mg were free of nausea at 2 hours compared with sumatriptan 100 mg (66% versus 58%, P=.043), sumatriptan 50 mg (68% versus 57%, P=.010), sumatriptan 25 mg (68% versus 59%, P=.017), and naratriptan 2.5 mg (59% versus 45%, P=.014). Averaging over the four posttreatment time points in the first 2 hours, significantly more patients treated with rizatriptan 10 mg were free of nausea compared with sumatriptan 100 mg (P=.004), sumatriptan 50 mg (P=.001), and naratriptan 2.5 mg (P=.015). No significant differences in nausea relief were seen between rizatriptan 10 mg and zolmitriptan 2.5 mg, either at 2 hours (65% versus 61%, P=.210) or over the first 2 hours (P=.781). Rates of treatment-emergent nausea at 2 hours ranged from 11% to 18% with placebo, from 5% to 13% with rizatriptan 10 mg, and from 10% to 20% with other comparator triptans. Conclusions.-Oral rizatriptan 10 mg was more effective than oral sumatriptan and naratriptan at eliminating nausea within 2 hours in patients who had it at baseline. Rates of emergent nausea in patients who were free of it at baseline were low, and no consistent differences were observed between active treatments.
引用
收藏
页码:754 / 763
页数:10
相关论文
共 50 条
  • [31] Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
    Lipton, Richard B.
    Cohen, Joshua M.
    Bibeau, Kristen
    Galic, Maja
    Seminerio, Michael J.
    Ramirez Campos, Verena
    Halker Singh, Rashmi B.
    Ailani, Jessica
    HEADACHE, 2020, 60 (10): : 2444 - 2453
  • [32] Effect of canakinumab on frailty: A post hoc analysis of the CANTOS trial
    Orkaby, Ariela R.
    Thomson, Aerin
    Macfadyen, Jean
    Besdine, Richard
    Forman, Daniel E.
    Travison, Thomas G.
    Ridker, Paul M.
    AGING CELL, 2024, 23 (01)
  • [33] EFFECT OF RANDOMIZED WITHDRAWAL OF BUDESONIDE ORAL SUSPENSION ON EFFICACY IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: POST HOC ANALYSIS OF HISTOLOGIC, SYMPTOM AND ENDOSCOPIC OUTCOMES
    Dellon, Evan S.
    Collins, Margaret H.
    Katzka, David A.
    Mukkada, Vincent A.
    Falk, Gary W.
    Goodwin, Bridgett
    Terreri, Brian
    Zhang, Wenwen
    Boules, Mena
    Desai, Nirav K.
    Hirano, Ikuo
    GASTROENTEROLOGY, 2022, 162 (07) : S238 - S238
  • [34] Does sexual functioning improve with migraine improvements and/or weight loss?-A post hoc analysis in the Women's Health and Migraine (WHAM) trial
    Schumacher, Leah
    Wing, Rena
    Thomas, J. Graham
    Pavlovic, Jelena
    Digre, Kathleen
    Farris, Samantha
    Steffen, Kristine
    Sarwer, David
    Bond, Dale
    OBESITY SCIENCE & PRACTICE, 2020, 6 (06): : 596 - 604
  • [35] Sustained response of galcanezumab in migraine prevention: Patient--level data from a post hoc analysis in patients with episodic or chronic migraine
    Tepper, Stewart J.
    Dong, Yan
    Vincent, Maurice
    Wietecha, Linda A.
    HEADACHE, 2023, 63 (10): : 1380 - 1390
  • [36] IS IRON DEFICIENCY ANEMIA RELATED TO MENSTRUAL MIGRAINE? - POST HOC ANALYSIS OF AN OBSERVATIONAL STUDY EVALUATING CLINICAL CHARACTERISTICS OF PATIENTS WITH MENSTRUAL MIGRAINE
    Vukovic-Cvetkovic, Vlasta
    Plavec, Davor
    Lovrencic-Huzjan, Arijana
    Galinovic, Ivana
    Seric, Vesna
    Demarin, Vida
    ACTA CLINICA CROATICA, 2010, 49 (04) : 389 - 394
  • [37] Monthly migraine days, acute medication use days, and migraine-specific quality of life in responders to atogepant: A post hoc analysis
    Dodick, D. W.
    Lipton, R. B.
    Nahas, S. J.
    Pozo-Rosich, P.
    McAllister, P.
    Mechtler, L. L.
    Ma, J.
    Dabruzzo, B. L.
    Dufek, M.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2022, 62 : 152 - 153
  • [38] Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
    Dodick, D.
    Lipton, R.
    Nahas, S.
    Pozo-Rosich, P.
    McAllister, P.
    Mechtler, L.
    Ma, J.
    Dabruzzo, B.
    Dufek, M.
    Severt, L.
    Finnegan, M.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [39] Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, randomized, cross-over studies
    G Allais
    V Tullo
    S Omboni
    C Benedetto
    G Sances
    D Zava
    MD Ferrari
    G Bussone
    The Journal of Headache and Pain, 2013, 14
  • [40] Post hoc analysis of progress: Evaluating the safety of atogepant in participants with chronic migraine and cardiovascular risk factors
    Best, Patricia
    Harriott, Andrea
    Monteith, Teshamae
    Tassorelli, Cristina
    Nahas, Stephanie
    Davidovic, Goran
    Liu, Yingyi
    Dabruzzo, Brett
    Ferreira, Rosa De Abreu
    Smith, Jonathan
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455